Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial

The Lancet

Volumn 376, Issue 9737, 2010, Pages 235-244

  Tutt, Andrew ^a   Robson, Mark ^b   Garber, Judy E ^c   Domchek, Susan M ^d   Audeh, M William ^e   Weitzel, Jeffrey N ^f   Friedlander, Michael ^g   Arun, Banu ^h   Loman, Niklas ⁱ   Schmutzler, Rita K ^j   Wardley, Andrew ^k   Mitchell, Gillian ^l   Earl, Helena ^m   Wickens, Mark ⁿ   Carmichael, James ⁿ  

^a Uro/Oncology Research   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g The Prince of Wales Cancer Centre   (Australia)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

^j UNIVERSITY OF COLOGNE   (Germany)

^k CHRISTIE HOSPITAL   (United Kingdom)

^l MacCallum Cancer Centre   (Australia)

^m UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁿ ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; OLAPARIB;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE FUNCTION; GENE LOSS; GENE MUTATION; GERMANY; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPAIN; SWEDEN; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES; VOMITING;

EID: 77955019276     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60892-6     Document Type: Article

References (41)

1. Colditz GA. Epidemiology of breast cancer. Findings from the nurses' health study. Cancer 1993; 71 (4 suppl): 1480-1489.
2. Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 2003; 362: 419-427
3. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093.
4. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71. (Pubitemid 24345325)
5. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792
6. Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 2006; 25: 5825-5831.
7. Moynahan ME, Chiu JW, Koller BH, Jasin M. BRCA1 controls homology-directed DNA repair. Mol Cell 1999; 4: 511-518.
8. Tutt A, Bertwistle D, Valentine J, et al. Mutation in BRCA2 stimulates error-prone homology-directed repair of DNA doublestrand breaks occurring between repeated sequences. Embo J 2001; 20: 4704-4716.
9. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homologydirected repair of chromosomal breaks. Mol Cell 2001; 7: 263-272.
10. Tutt A, Gabriel A, Bertwistle D, et al. Absence of BRCA2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr Biol 1999; 9: 1107-1110.
11. Tutt AN, van Oostrom CT, Ross GM, van Steeg H, Ashworth A. Disruption of BRCA2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation. EMBO Rep 2002; 3: 255-260.
12. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002; 8: 571-576.
13. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997; 57: 1222-1227.
14. Tirkkonen M, Kainu T, Loman N, et al. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer 1999; 24: 56-61.
15. Jonkers J, Meuwissen R, van Der Gulden H, Peterse H, van Der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 5: 5.
16. Liu X, Holstege H, van der Gulden H, et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 2007; 104: 12111-12116.
17. Collins N, McManus R, Wooster R, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995; 10: 1673-1675.
18. Cornelis RS, Neuhausen SL, Johansson O, et al. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer 1995; 13: 203-210.
19. Merajver SD, Frank TS, Xu J, Pham TM, et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1995; 1: 539-544.
20. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005; 70: 139-148.
21. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-698.
22. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
23. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-917.
24. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
26. Newcombe RG, Altman DG. Proportions and their differences. In: Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence, 2nd edn. London: BMJ Books, 2000: 45-56.
27. Osin PP, Lakhani SR. The pathology of familial breast cancer: Immunohistochemistry and molecular analysis. Breast Cancer Res 1999; 1: 36-40.
28. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-2318.
29. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; published online July 6; DOI:10.1016/S0140-6736(10)60893-60898.
30. Gronwald J, Byrski T, Huzarski T, et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 2009; 27 (15S): 502 (abstr).
31. Byrski T, Foszczynska-Kloda M, Huzarski T, et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). J Clin Oncol 2009; 27 (15S): 1099 (abstr).
32. Kriege M, Seynaeve C, Meijers-Heijboer H, et al. Sensitivity to firstline chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 3764-3771.
33. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracyclineand taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536-542.
34. Degardin M, Bonneterre J, Hecquet B, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994; 5: 423-426.
35. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25: 3407-3414.
36. Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115.
37. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-1120.
38. Sakai W, Swisher EM, Jacquemont C, et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 2009; 69: 6381-6386.
39. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68: 2581-2586.
40. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519.
41. Mendes-Pereira A, Martin S, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1: 1-8.